Zoetis Inc. $ZTS Shares Acquired by Boston Trust Walden Corp

Boston Trust Walden Corp grew its stake in Zoetis Inc. (NYSE:ZTS) by 94.8% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 95,468 shares of the company’s stock after buying an additional 46,450 shares during the quarter. Boston Trust Walden Corp’s holdings in Zoetis were worth $14,888,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ZTS. Nuveen LLC purchased a new position in shares of Zoetis in the 1st quarter valued at about $616,375,000. Mackenzie Financial Corp increased its stake in shares of Zoetis by 4,158.3% in the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock valued at $300,481,000 after purchasing an additional 1,782,110 shares in the last quarter. Polen Capital Management LLC increased its stake in shares of Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after purchasing an additional 1,313,653 shares in the last quarter. Amundi increased its stake in shares of Zoetis by 30.8% in the 1st quarter. Amundi now owns 3,595,628 shares of the company’s stock valued at $575,691,000 after purchasing an additional 846,909 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd increased its stake in shares of Zoetis by 475.9% in the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company’s stock valued at $148,228,000 after purchasing an additional 743,926 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $143.45 on Wednesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The business has a 50 day simple moving average of $148.98 and a 200-day simple moving average of $154.11. The firm has a market capitalization of $63.58 billion, a PE ratio of 24.69, a price-to-earnings-growth ratio of 2.28 and a beta of 0.90. Zoetis Inc. has a 1 year low of $139.34 and a 1 year high of $196.55.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business’s revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. Zoetis’s dividend payout ratio is 34.42%.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and cut their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Finally, Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $196.71.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.